This history of rapid acceleration suggests that Eli Lilly is primed for another massive breakout as new catalysts emerge.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Eli Lilly announced an acquisition of an innovative new autoimmune drug.

Eli Lilly and Company LLY announced robust fourth-quarter results on Feb. 4. Lilly beat estimates for both earnings and sales and issued an upbeat guidance for 2026. Adjusted earnings per share of $7.

Late last year, Lilly was the first pharmaceutical stock to reach a $1 trillion valuation.

Novo Nordisk just did Eli Lilly stock a huge favor.

Despite a "Very High" valuation following its recent surge, the stock remains attractive due to its "Very Strong" operational health and robust pipeline.

Eli Lilly (LLY) stock announced seventh Innovent partnership with $350M upfront and $8.5B milestone potential for joint ...

Is there another beat-and-raise in the pharmaceutical giant's near future?

Eli Lilly rated SELL: rich valuation priced for perfection, rising GLP-1 competition, pricing pressure, and patent-cliff risk. Click here to read more on LLY stock.

Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...

Eli Lilly has long been gearing up for the launch of orforglipron, announcing as early as February 2024 that it was ramping up manufacturing investments for the weight-loss pill.